Search hospitals > Michigan > Ann Arbor
VA Ann Arbor Healthcare System, Ann Arbor, MI
Claim this profileAnn Arbor, Michigan 48105
Global Leader in Lung Cancer
Global Leader in Prostate Cancer
Conducts research for Diabetes
Conducts research for Cancer
Conducts research for Post-Traumatic Stress Disorder
254 reported clinical trials
24 medical researchers
Summary
VA Ann Arbor Healthcare System, Ann Arbor, MI is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Lung Cancer, Prostate Cancer, Diabetes, Cancer, Post-Traumatic Stress Disorder and other specialties. VA Ann Arbor Healthcare System, Ann Arbor, MI is involved with conducting 254 clinical trials across 274 conditions. There are 24 research doctors associated with this hospital, such as David Elliott, Michelle Mierzwa, M.D., Paul N Pfeiffer, MD MS, and Nithya Ramnath, MBBS.Area of expertise
1Lung Cancer
Global LeaderStage I
Stage II
Stage III
2Prostate Cancer
Global LeaderStage IV
MLH1 positive
MSH2 positive
Top PIs
David ElliottVA Ann Arbor Healthcare System2 years of reported clinical research
Studies Prostate Cancer
Studies Celiac Disease
3 reported clinical trials
7 drugs studied
Michelle Mierzwa, M.D.University of Michigan Rogel Cancer Center1 year of reported clinical research
Studies Oropharyngeal Cancer
Studies Squamous Cell Carcinoma
4 reported clinical trials
10 drugs studied
Paul N Pfeiffer, MD MSVA Ann Arbor Healthcare System, Ann Arbor, MI5 years of reported clinical research
Studies Loneliness
Studies Overmedication
3 reported clinical trials
6 drugs studied
Nithya Ramnath, MBBSThe University of Michigan Rogel Cancer Center5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
2 reported clinical trials
3 drugs studied
Clinical Trials running at VA Ann Arbor Healthcare System, Ann Arbor, MI
Prostate Cancer
Lung Cancer
Sleep Apnea
Parkinson's Disease
Respiratory Infection
Coronavirus
Diabetic Kidney Disease
Small Cell Lung Cancer
Rheumatoid Arthritis
Chronic Obstructive Pulmonary Disease
Pembrolizumab
for Prostate Cancer
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting2 awards Phase 23 criteria
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting1 award Phase 2
Systemic + Local Therapy
for Prostate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Recruiting1 award Phase 2 & 33 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at VA Ann Arbor Healthcare System, Ann Arbor, MI?
VA Ann Arbor Healthcare System, Ann Arbor, MI is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Lung Cancer, Prostate Cancer, Diabetes, Cancer, Post-Traumatic Stress Disorder and other specialties. VA Ann Arbor Healthcare System, Ann Arbor, MI is involved with conducting 254 clinical trials across 274 conditions. There are 24 research doctors associated with this hospital, such as David Elliott, Michelle Mierzwa, M.D., Paul N Pfeiffer, MD MS, and Nithya Ramnath, MBBS.